Articles tagged "Immunosuppression"

2015 American Transplant Congress
microRNA-494 Promotes Cyclosporine-Induced Nephrotoxicity and Epithelial to Mesenchymal Transition By Inhibiting PTEN
J. Yuan,¹ C. Benway,^1,2 J. Bagley,¹ J. Iacomini.^1,2
¹Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, Boston, MA; ²Sackler School of Biomedical Sciences Programs in Immunology and Genetics, Tufts University School of Medicine, Boston, MA.
Purpose: A major complication associated with cyclosporine (CsA) treatment is nephrotoxicity. MicroRNAs (miRs) have been shown to play an important role in various pathological conditions,…
2015 American Transplant Congress
Evaluation of Medication Regimen Complexity Over Time Following Heart Re-Transplantation
B. Bryant,¹ A. Libby,¹ R. Page,¹ J. Lindenfeld,² C. Aquilante.¹
¹University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO; ²University of Colorado School of Medicine, Aurora, CO.
Medication regimen complexity (MRC) includes many characteristics of a drug regimen. Previously, we showed that MRC is high and persists over time after primary heart…
2015 American Transplant Congress
Kidney Transplant Function After Late Conversion to Belatacept (Nulojix®)
S. Brakemeier,¹ M. Dürr,¹ M. Wiesener,² B. Tobias,² K. Budde,¹ B. Klemens.¹
¹Nephrology, Charite Campus Mitte, Berlin, Germany; ²Nephrology, University Erlangen-Nuremberg, Erlangen, Germany.
Introduction: In the long-term follow up of kidney transplants, chronic transplant nephropathy often in combination with CNI-toxicity is a major problem. With declining transplant function…
2015 American Transplant Congress
No Pharmacokinetic Interaction Between Pantoprazole and Mycophenolic Acid in Renal Transplant Patents: A Randomized Crossover Study
O. Rissling, P. Glander, P. Hambach, M. Mai, S. Brakemeier, D. Klonower, F. Halleck, E. Singer, E. Schrezenmeier, M. Duerr, H. Neumayer, K. Budde.
Department of Nephrology, Charité University Hospital, Berlin, Germany.
Mycophenolic acid (MPA) is used as an immunosuppressive agent in renal transplant (tx) patients (pts). 2 formulations are on the market: The prodrug Mycophenolate-Mofetil (MMF)…
2015 American Transplant Congress
Patient Self-Reported Adherence to and Perceptions Towards Immunosuppressive Medications at the Outpatient Renal Transplant Clinic at St. Joseph's Healthcare Hamilton (SJHH)
K. Kak,¹ C. Burger,¹ D. Treleaven,² C. Wallace.¹
¹Pharmacy, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada; ²Medicine, McMaster University, Hamilton, ON, Canada.
Objectives To gain insight into the immunosuppressant adherence of patients followed by the Outpatient Renal Transplant Clinic at St. Joseph's Healthcare Hamilton (SJHH) and to…
2015 American Transplant Congress
CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment
R. Hotta,¹ M. Ohira,² T. Matsuura,¹ I. Muraoka,¹ P. Tryphonopoulos,¹ J. Fan,¹ A. Tekin,¹ H. Ohdan,² A. Tzakis,³ R. Vianna,¹ S. Nishida.¹
¹University of Miami, Miami, FL; ²Hiroshima University, Hiroshima, Japan; ³Cleveland Clinic Florida, Weston, FL.
Background: T-cell depleting strategies have become an integral part of immunosuppressive regimens in organ transplantation. Alemtuzumab is a humanized monoclonal antibody against CD52, a cell-surface…
2015 American Transplant Congress
2-Year Results on Renal Function and Safety for Everolimus plus Reduced-Exposure Calcineurin Inhibitor in Living Donor Kidney Transplant Recipients
T. Yagisawa,¹ N. Ishikawa,¹ N. Goto,² I. Nakajima,³ O. Kamisawa,⁴ S. Fuchinoue.³
¹Division of Renal and Transplantation, Jichi Medical University, Shimotsuke, Japan; ²Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan; ³Surgery, Kidney Center, Tokyo Women's University, Tokyo, Japan; ⁴Medical Division, Novartis Pharma K.K., Tokyo, Japan.
Purpose: The long-term effects of everolimus (EVR) with reduced cyclosporine (rCsA) exposure over 24 months on renal function and safety (viral infection) were assessed in…
2015 American Transplant Congress
T-Cell Immune Function Vs. Gene Expression Profiling for Heart Transplant Rejection
M. Luu, M. Kittleson, J. Patel, F. Liou, S. Siddiqui, L. Piponniau, A. Hage, D. Chang, L. Czer, A. Trento, J. Kobashigawa.
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: Non-invasive immune monitoring of heart transplant (HTx) patients (pts) is increasing in use. The AlloMap® blood test has proven helpful in surveillance of cardiac…
2015 American Transplant Congress
Post-Kidney Transplant Infections in Desensitized Patients Receiving Thymoglobulin or Daclizumab Induction: Results of a Randomized Clinical Trial
B. Orandi,¹ J. Locke,² E. Kraus,³ B. Lonze,¹ N. Desai,¹ N. Dagher,¹ N. Alachkar,³ C. Simpkins,⁴ F. Naqvi,³ D. Segev,¹ R. Montgomery,¹ R. Avery.³
¹Department of Surgery, Johns Hopkins University, Baltimore; ²Department of Surgery, University of Alabama--Birmingham, Birmingham; ³Department of Medicine, Johns Hopkins University, Baltimore; ⁴Department of Surgery, Dartmouth, Lebanon.
Live donor kidney transplant recipients requiring desensitization for donor-specific antibody, who were enrolled in a single-center randomized trial of thymoglobulin vs. daclizumab induction, were evaluated…
2015 American Transplant Congress
Evaluation of Donor-Specific Antibodies Through 7 Years With Belatacept in BENEFIT and BENEFIT-EXT
R. Bray,¹ H. Gebel,¹ R. Townsend,² U. Meier-Kriesche,² C. Larsen.¹
¹Emory University, Atlanta; ²Bristol-Myers Squibb, Lawrenceville.
Purpose: The development of donor-specific antibody (DSA) is linked to an increased risk of antibody-mediated rejection and graft failure. The 3 year intent-to-treat results from…